MindWalk (NASDAQ:HYFT) Announces Earnings Results

MindWalk (NASDAQ:HYFT) posted its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02), Zacks reports. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.50 million. MindWalk had a negative net margin of 145.58% and a negative return on equity of 56.75%.

MindWalk Stock Performance

Shares of HYFT stock traded down $0.10 during midday trading on Friday, reaching $1.22. 287,480 shares of the company were exchanged, compared to its average volume of 604,301. The business has a 50 day simple moving average of $1.54. The stock has a market capitalization of $56.08 million, a P/E ratio of -2.02 and a beta of 0.58. MindWalk has a 12 month low of $0.32 and a 12 month high of $3.25. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.09 and a current ratio of 4.19.

Analyst Ratings Changes

HYFT has been the subject of a number of recent research reports. UBS Group restated a “buy” rating on shares of MindWalk in a research note on Friday. Zacks Research upgraded shares of MindWalk from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research report on Friday. Finally, Weiss Ratings assumed coverage on shares of MindWalk in a research note on Wednesday, January 14th. They set a “sell (d-)” rating for the company. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On MindWalk

A number of institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its position in shares of MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after purchasing an additional 96,018 shares during the period. Bridgeway Capital Management LLC bought a new position in MindWalk during the fourth quarter valued at about $91,000. XTX Topco Ltd grew its holdings in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the period. Virtu Financial LLC bought a new stake in MindWalk in the fourth quarter worth about $51,000. Finally, Bank of Montreal Can raised its position in MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares in the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.